Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Gwolf who wrote (1096)	6/18/1998 9:49:00 AM
From: OFW	Read Replies (2) \| Respond to of 5402

NEWS OUT! PASADENA, Calif.--(BUSINESS WIRE)--June 18, 1998--Sanguine Corp. (OTC BB:SGNC) and Battelle Memorial Research Institute Thursday announced that a completed contract has been signed and that the funding is now in place for animal testing of emulsions for use as oxygen-carrying blood substitutes. Battelle, the world's oldest and largest independent contract research group of scientists, engineers, and other specialists, has provided research since 1994 in support of Sanguine's efforts to develop, manufacture and market a proprietary synthetic red blood cell substitute. According to Dr. Thomas C. Drees, president and chief executive officer of Sanguine Corp., "Sanguine estimates the annual worldwide market potential for this product at $20 billion. In the United States alone nearly everyone who reaches the age of 75 will need blood, plasma, or one of their components at least once in his lifetime." Drees, who has been in the forefront of the artificial blood products field for more than 20 years, was the president and CEO of the only company to have obtained FDA approval for a synthetic blood product to date. CONTACT: mklpr, Salt Lake City Mary Kay Lazarus, 801/328-8899 09:30 EDT JUNE 18, 1998